Arcutis Biotherapeutics, Inc. ARQT Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Arcutis Biotherapeutics, Inc. (ARQT) reported accretion (amortization) of discounts and premiums, investments of $182K in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 78.8% year-over-year, from $859K to $182K.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a -11.6% compound annual growth rate (CAGR), from -$3.45M to $2.11M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Reflects the periodic adjustment to the carrying value of investment securities to reflect the amortization of premiums or the accretion of discounts over the life of the instrument. This non-cash adjustment reconciles the difference between the purchase price and the face value of debt securities held in the investment portfolio. It provides insight into the effective yield and interest income recognition of the company's treasury assets.